Delaying cefiderocol resistance development in NDM-producing Enterobacter cloacae complex by combining cefiderocol with aztreonam in vitro.
Lisa Göpel, Minh Thu Tran Nguyen, Tung Tran Thanh, Susanne HauswaldtiD, Özge Nur Canbulat, Jan RuppiD, Sébastien BoutiniD, Dennis NurjadiiD
Abstract
BackgroundThe rapid development of cefiderocol resistance poses a significant concern, particularly in Enterobacterales that produce New Delhi metallo-{beta}-lactamase (NDM). This study explores the potential of inhibiting the development of cefiderocol resistance by combining cefiderocol with aztreonam. MethodsA resistance induction experiment using 20 clinical isolates was performed to assess the impact of cefiderocol-aztreonam on preventing cefiderocol resistance development at 4x and 10x cefiderocol MIC, with and without aztreonam (2, 4, 8 {micro}g/ml). Additionally, serial passaging with doubling cefiderocol concentrations was performed with and without aztreonam. Whole genome sequencing (WGS) was performed to identify potential genetic factors associated with the phenotype. ResultsAmong the 20 E. cloacae complex isolates, 40% (8/20) exhibited a significant reduction in cefiderocol MIC ([≥]4-fold MIC reduction) in the presence of 4 {micro}g/ml aztreonam. Combining cefiderocol with a fixed concentration of 4 {micro}g/ml aztreonam inhibited cefiderocol resistance development in these eight isolates at an inoculum of 107 cfu/ml. Additional resistance induction experiments through serial passaging indicated a delayed emergence of cefiderocol-resistant clones when cefiderocol was combined with aztreonam. WGS analysis revealed a significant positive association between blaCTX-M-15, blaOXA-1, and other co-localized genes with a substantial MIC reduction for cefiderocol-aztreonam compared to cefiderocol alone. ConclusionOur study suggested that cefiderocol resistance development in NDM-producing E. cloacae complex can be delayed or inhibited by combining cefiderocol with aztreonam, even in the presence of multiple {beta}-lactamase genes. A MIC reduction of at least 4-fold emerges as the most reliable predictor for inhibiting resistance development with this dual {beta}-lactam combination.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Comparison of multiple cefiderocol susceptibility testing methods against genomic determinants of resistance in blaNDM carbapenemase producing Enterobacterales
Caitlin Duggan, Daire M. Cantillon, … Thomas Edwards·bioRxiv·Jan 27, 2026
- Evolution of β-lactamase mediated cefiderocol resistance
Christopher Fröhlich, Vidar Sørum, … Ørjan Samuelsen·Journal of Antimicrobial ChemotherapyPeer-reviewed·Jul 11, 2022
- Mechanisms involved in cefiderocol resistance in French Pseudomonas aeruginosa clinical strains
Emma GAUTHIER, Matthieu PISANI, … Katy Jeannot·Antimicrobial Agents and ChemotherapyPeer-reviewed·Jul 10, 2026
- Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms
Justin Halim, Andrew Patrick Keane, … Valerie J. Carabetta·Journal of Antimicrobial ChemotherapyPeer-reviewed·Aug 7, 2025
- In vitro activity of cefiderocol against carbapenemase-producing and meropenem-nonsusceptible gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance (JARBS-GNR)
Shizuo Kayama, Sayoko Kawakami, … Motoyuki Sugai·Journal of Global Antimicrobial ResistancePeer-reviewed·May 22, 2024
- In-vitro activity of Cefiderocol against clinical isolates of meropenem-resistant Klebsiella pneumoniae from India.
K. Borde, K. A. Mohammed, … D. Mathai·bioRxiv·Sep 16, 2022